Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy

Bibliography

• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29
   PubMed Web of Science ®Google Scholar
• Nikolaou V, Stratigos AJ. Emerging trends in the epidemiology of melanoma. Br J Dermatol 2014;170(1):11-19
   PubMed Web of Science ®Google Scholar
• Smoller BR. Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mod Pathol 2006;19(Suppl 2):S34-40
   Google Scholar
• Populo H, Soares P, Lopes JM. Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert Opin Ther Targets 2012;16(7):689-705
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199-206
   PubMed Web of Science ®Google Scholar
• Lopez-Bergami P, Fitchman B, Ronai Z. Understanding signaling cascades in melanoma. Photochem Photobiol 2008;84(2):289-306
   PubMed Web of Science ®Google Scholar
• Bertolotto C. Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica 2013;2013:22
   Google Scholar
• Populo H, Boaventura P, Vinagre J, et al. TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J Invest Dermatol 2014;134(8):2251-7
   PubMed Web of Science ®Google Scholar
• Elder DE. Precursors to melanoma and their mimics: nevi of special sites. Modern pathology Inc 2006;19(Suppl 2):S4-20
   Google Scholar
• Kumar R, Angelini S, Snellman E, et al. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 2004;122(2):342-8
   PubMed Web of Science ®Google Scholar
• Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436(7051):720-4
   PubMed Web of Science ®Google Scholar
• Vredeveld LC, Possik PA, Smit MA, et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 2012;26(10):1055-69
   Google Scholar
• Populo H, Soares P, Faustino A, et al. mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment Cell Melanoma Res 2011;24(1):254-7
   Google Scholar
• Olszanski AJ. Current and future roles of targeted therapy and immunotherapy in advanced melanoma. J manag Care Spec Pharm 2014;20(4):346-56
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367(2):107-14
   PubMed Web of Science ®Google Scholar
• Ballantyne AD, Garnock-Jones KP. Dabrafenib: first global approval. Drugs 2013;73(12):1367-76
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm412861.htm
   Google Scholar
• Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008;49(Suppl 2):24S-42S
   Google Scholar
• Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013;4:e532
   PubMed Web of Science ®Google Scholar
• Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 2013;123(9):3664-71
   PubMed Web of Science ®Google Scholar
• Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008;8(11):851-64
   PubMed Web of Science ®Google Scholar
• Scott DA, Richardson AD, Filipp FV, et al. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem 2011;286(49):42626-34
   Google Scholar
• Kluza J, Corazao-Rozas P, Touil Y, et al. Inactivation of the HIF-1alpha/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res 2012;72(19):5035-47
   PubMed Web of Science ®Google Scholar
• Baudy AR, Dogan T, Flores-Mercado JE, et al. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI research 2012;2(1):22
   Google Scholar
• Hall A, Meyle KD, Lange MK, et al. Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget 2013;4(4):584-99
   Google Scholar
• Kumar SM, Yu H, Edwards R, et al. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res 2007;67(7):3177-84
   PubMed Web of Science ®Google Scholar
• Kuphal S, Winklmeier A, Warnecke C, et al. Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 2010;46(6):1159-69
   Google Scholar
• Slominski A, Kim TK, Brozyna AA, et al. The role of melanogenesis in regulation of melanoma behavior: Melanogenesis leads to stimulation of HIF-1alpha expression and HIF-dependent attendant pathways. Archives of biochemistry and biophysics 2014;563:79-93
   PubMed Web of Science ®Google Scholar
• Kim JW, Tchernyshyov I, Semenza GL, et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3(3):177-85
   PubMed Web of Science ®Google Scholar
• Lu CW, Lin SC, Chen KF, et al. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 2008;283(42):28106-14
   PubMed Web of Science ®Google Scholar
• Patel MS, Korotchkina LG. Regulation of the pyruvate dehydrogenase complex. Biochem Soc Trans 2006;34(Pt 2):217-22
   PubMedGoogle Scholar
• Bowker-Kinley MM, Davis WI, Wu P, et al. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 1998;329(Pt 1):191-6
   PubMedGoogle Scholar
• Papandreou I, Goliasova T, Denko NC. Anticancer drugs that target metabolism: Is dichloroacetate the new paradigm? Int J Cancer 2011;128(5):1001-8
   PubMed Web of Science ®Google Scholar
• Zhang S, Hulver MW, McMillan RP, et al. The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility. Nutrition & metabolism 2014;11(1):10
   Google Scholar
• Wigfield SM, Winter SC, Giatromanolaki A, et al. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. Br J Cancer 2008;98(12):1975-84
   PubMed Web of Science ®Google Scholar
• Lu CW, Lin SC, Chien CW, et al. Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer. Am J Pathol 2011;179(3):1405-14
   PubMed Web of Science ®Google Scholar
• Baumunk D, Reichelt U, Hildebrandt J, et al. Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC). World J Urol 2013;31(5):1191-6
   Google Scholar
• Hur H, Xuan Y, Kim YB, et al. Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int J Oncol 2013;42(1):44-54
   PubMedGoogle Scholar
• Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11(1):37-51
   PubMed Web of Science ®Google Scholar
• Kankotia S, Stacpoole PW. Dichloroacetate and cancer: New home for an orphan drug? Biochimica et biophysica acta 2014;1846(2):617-29
   Google Scholar
• Sutendra G, Dromparis P, Kinnaird A, et al. Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer. Oncogene 2013;32(13):1638-50
   Google Scholar
• Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010;2(31):31ra34
   PubMed Web of Science ®Google Scholar
• Castro P, Rebocho AP, Soares RJ, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):213-20
   PubMed Web of Science ®Google Scholar
• Sun W, Zhou S, Chang SS, et al. Mitochondrial mutations contribute to HIF1alpha accumulation via increased reactive oxygen species and up-regulated pyruvate dehydrogenase kinase 2 in head and neck squamous cell carcinoma. Clin Cancer Res 2009;15(2):476-84
   Google Scholar
• Cairns RA, Bennewith KL, Graves EE, et al. Pharmacologically increased tumor hypoxia can be measured by 18F-Fluoroazomycin arabinoside positron emission tomography and enhances tumor response to hypoxic cytotoxin PR-104. Clin Cancer Res 2009;15(23):7170-4
   Google Scholar
• Sun RC, Board PG, Blackburn AC. Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells. Mol Cancer 2011;10:142
   PubMed Web of Science ®Google Scholar
• Shahrzad S, Lacombe K, Adamcic U, et al. Sodium dichloroacetate (DCA) reduces apoptosis in colorectal tumor hypoxia. Cancer Lett 2010;297(1):75-83
   PubMed Web of Science ®Google Scholar
• Abildgaard C, Dahl C, Basse AL, et al. Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition. J Transl Med 2014;12:247
   Google Scholar
• Populo H, Tavares S, Faustino A, et al. GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells. Peer J 2013;1:e104
   Google Scholar
• Sutendra G, Kinnaird A, Dromparis P, et al. A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell 2014;158(1):84-97
   PubMed Web of Science ®Google Scholar
• Kim JW, Dang CV. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 2005;30(3):142-50
   PubMed Web of Science ®Google Scholar
• Xuan Y, Hur H, Ham IH, et al. Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism. Exp Cell Res 2014;321(2):219-30
   PubMed Web of Science ®Google Scholar
• Hong SE, Shin KS, Lee YH, et al. Inhibition of S6K1 enhances dichloroacetate-induced cell death. J Cancer Res Clin Oncol 2014. [Epub ahead of print]
   Google Scholar